Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217912 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTRAB9ATSHRMEN1 | |
| SCHEMBL14353368 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTRAB9ATSHRMEN1 | |
| SCHEMBL30417908 | 0.84 | L3MBTL1 (0.41) | SMN1; SMN2MAPTTSHRALDH1A1EGFR | |
| SCHEMBL9958035 | 0.79 | FLT3 (0.40) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL9958042 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTRAB9ATSHRMEN1 | |
| SCHEMBL10805388 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2MAPTRAB9ATSHRMEN1 | |
| SCHEMBL9958245 | 0.75 | FLT3 (0.43) | TSHRMEN1KMT2A | |
| SCHEMBL1255130 | 0.75 | GAPDH (0.50) | SMN1; SMN2MAPTRAB9AMEN1NPC1 | |
| SCHEMBL1888991 | 0.71 | MAPT (0.69) | SMN1; SMN2MAPTRAB9ATSHRMEN1 | |
| SCHEMBL21776829 | 0.70 | RARA (0.48) | MAPTTSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SMN1; SMN2 2990/4885MAPT 72/4885RAB9A 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.